FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005204003> ?p ?o ?g. }

• W2005204003 endingPage "176" @default.
• W2005204003 startingPage "165" @default.
• W2005204003 abstract "We investigated the effect of intramuscular injections of long-acting bromocriptine in patients with macroadenomas.Thirty patients with PRL-secreting pituitary macroadenomas were treated with repeated 4-weekly intramuscular injections of 50 or 100 mg of a long-acting, repeatable bromocriptine formulation for six to 37 injections, amounting to a total of 473 injections. Twenty patients received parenteral bromocriptine as primary therapy, ten had persisting hyperprolactinemia after previous therapies including pituitary surgery (n = 7), oral bromocriptine (7), and pituitary irradiation (2).A PRL day profile was obtained and the patients' clinical status and history were documented, at intervals. Detailed clinical, laboratory, and radiological (pituitary nuclear magnetic resonance or computed tomography scan) evaluations were performed at baseline, after 1 injection and every 6th injection thereafter.In all patients PRL was suppressed from a mean +/- SEM pretreatment level of 32,620 +/- 8680 to 4480 +/- 1140 mU/I on the third day after the first injection. In 12 patients PRL levels normalized (< 400 mU/I) with the first to fourth injection, in three additional patients PRL levels normalized after 8-15 months. In 19 patients PRL was suppressed to less than 1000 mU/l. In three patients PRL did not decrease to less than 50% of pretreatment; in two of them on oral bromocriptine prior to this study there had been a comparable low efficacy. Of 28 patients with macroadenomas (median height 22 mm) tumour shrinkage was evident in 15 by nuclear magnetic resonance or computed tomography scan 28 days after the first injection, and in three additional patients after 6 months. There was further regression in seven cases after 12, 18 or 24 injections. Adenoma size (mean +/- SEM) decreased to 66 +/- 7% of the pretreatment value. The 40 adverse events noted in 20 of 30 patients during 24 hours after the first injection were similar to known side-effects of oral bromocriptine, nausea and postural hypotension being the most frequent. With repeated injections, on average 0.6 adverse events were noted per injection (mostly mild asthenia). There were no local adverse reactions at the injection site.We conclude that long-acting repeatable bromocriptine in patients with macroprolactinomas offers a safe and efficacious primary treatment that ensures compliance and gives long-term control. Adverse reactions are comparable to oral bromocriptine but subside with repeated injections." @default.
• W2005204003 created "2016-06-24" @default.
• W2005204003 creator A5005559815 @default.
• W2005204003 creator A5017787563 @default.
• W2005204003 creator A5018974244 @default.
• W2005204003 creator A5023848154 @default.
• W2005204003 creator A5032742966 @default.
• W2005204003 creator A5040006431 @default.
• W2005204003 creator A5056687645 @default.
• W2005204003 creator A5073136435 @default.
• W2005204003 date "1993-02-01" @default.
• W2005204003 modified "2023-09-24" @default.
• W2005204003 title "Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years" @default.
• W2005204003 cites W1965908443 @default.
• W2005204003 cites W1968674415 @default.
• W2005204003 cites W1981320875 @default.
• W2005204003 cites W1981882991 @default.
• W2005204003 cites W1982582424 @default.
• W2005204003 cites W1985514809 @default.
• W2005204003 cites W1996287756 @default.
• W2005204003 cites W2002117165 @default.
• W2005204003 cites W2003130090 @default.
• W2005204003 cites W2010563165 @default.
• W2005204003 cites W2016210258 @default.
• W2005204003 cites W2031414041 @default.
• W2005204003 cites W2037961396 @default.
• W2005204003 cites W2047557211 @default.
• W2005204003 cites W2057921067 @default.
• W2005204003 cites W2065430504 @default.
• W2005204003 cites W2067202852 @default.
• W2005204003 cites W2075593856 @default.
• W2005204003 cites W2077715496 @default.
• W2005204003 cites W2079391734 @default.
• W2005204003 cites W2081972040 @default.
• W2005204003 cites W2085121249 @default.
• W2005204003 cites W2085999153 @default.
• W2005204003 cites W2088735547 @default.
• W2005204003 cites W2097313178 @default.
• W2005204003 cites W2108783710 @default.
• W2005204003 cites W2144245982 @default.
• W2005204003 cites W2145502085 @default.
• W2005204003 cites W2340944854 @default.
• W2005204003 cites W2410060354 @default.
• W2005204003 cites W2410475400 @default.
• W2005204003 cites W4230940446 @default.
• W2005204003 doi "https://doi.org/10.1111/j.1365-2265.1993.tb00989.x" @default.
• W2005204003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8435897" @default.
• W2005204003 hasPublicationYear "1993" @default.
• W2005204003 type Work @default.
• W2005204003 sameAs 2005204003 @default.
• W2005204003 citedByCount "10" @default.
• W2005204003 countsByYear W20052040032012 @default.
• W2005204003 crossrefType "journal-article" @default.
• W2005204003 hasAuthorship W2005204003A5005559815 @default.
• W2005204003 hasAuthorship W2005204003A5017787563 @default.
• W2005204003 hasAuthorship W2005204003A5018974244 @default.
• W2005204003 hasAuthorship W2005204003A5023848154 @default.
• W2005204003 hasAuthorship W2005204003A5032742966 @default.
• W2005204003 hasAuthorship W2005204003A5040006431 @default.
• W2005204003 hasAuthorship W2005204003A5056687645 @default.
• W2005204003 hasAuthorship W2005204003A5073136435 @default.
• W2005204003 hasConcept C126322002 @default.
• W2005204003 hasConcept C126838900 @default.
• W2005204003 hasConcept C134018914 @default.
• W2005204003 hasConcept C143409427 @default.
• W2005204003 hasConcept C2776291583 @default.
• W2005204003 hasConcept C2776856834 @default.
• W2005204003 hasConcept C2777658017 @default.
• W2005204003 hasConcept C2779064019 @default.
• W2005204003 hasConcept C2989005 @default.
• W2005204003 hasConcept C71315377 @default.
• W2005204003 hasConcept C71924100 @default.
• W2005204003 hasConcept C90924648 @default.
• W2005204003 hasConceptScore W2005204003C126322002 @default.
• W2005204003 hasConceptScore W2005204003C126838900 @default.
• W2005204003 hasConceptScore W2005204003C134018914 @default.
• W2005204003 hasConceptScore W2005204003C143409427 @default.
• W2005204003 hasConceptScore W2005204003C2776291583 @default.
• W2005204003 hasConceptScore W2005204003C2776856834 @default.
• W2005204003 hasConceptScore W2005204003C2777658017 @default.
• W2005204003 hasConceptScore W2005204003C2779064019 @default.
• W2005204003 hasConceptScore W2005204003C2989005 @default.
• W2005204003 hasConceptScore W2005204003C71315377 @default.
• W2005204003 hasConceptScore W2005204003C71924100 @default.
• W2005204003 hasConceptScore W2005204003C90924648 @default.
• W2005204003 hasIssue "2" @default.
• W2005204003 hasLocation W20052040031 @default.
• W2005204003 hasLocation W20052040032 @default.
• W2005204003 hasOpenAccess W2005204003 @default.
• W2005204003 hasPrimaryLocation W20052040031 @default.
• W2005204003 hasRelatedWork W1998726554 @default.
• W2005204003 hasRelatedWork W2000833909 @default.
• W2005204003 hasRelatedWork W2035004278 @default.
• W2005204003 hasRelatedWork W2076115378 @default.
• W2005204003 hasRelatedWork W2081928466 @default.
• W2005204003 hasRelatedWork W2084962092 @default.
• W2005204003 hasRelatedWork W2094766549 @default.
• W2005204003 hasRelatedWork W2121023379 @default.

• next